FCF Healthcare & Life Sciences Venture Capital Monitor – Europe – 05/2025 published

FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Healthcare & Life Sciences Venture Capital Monitor – Europe 05/2024”.

The Monitor is a monthly published overview of venture capital trends in the European Healthcare & Life Sciences sector.

As of the end of May 2025 we identified the following current VC trends in Europe:

  • Total Healthcare & Life Sciences funding reached EUR 5,149m (+26% vs. 2024)
  • Biotech/Pharma received 36% of the total investment volume (EUR 1,886m) with metabolic disorders (including Diabetes, Obesity) being the leading indication (28%)
  • In May, Azafaros (Netherlands) secured the highest transaction volume with EUR 132m, followed by GlycoEra (Switzerland) with EUR 115m and CellCentric (Great Britain) with EUR 106m
  • GV (United States) is the most active investor (by deal volume in 2025), followed by Alphabet (United States) and Thrive Capital (United States)

To access the full report, please click here.

By Mathias Klozenbücher and Johannes Link